Nitric Oxide Articles
Substitute As Good As Blood In Trauma Patients
12 August 1998
Pfizer's Viagra Backed By CPMP
4 June 1998
NitroMed Completes $12 Million Financing
15 May 1998
Europe Sees Biotech Industry Forging Ahead
7 May 1998
GW Drops 546C88 for Septic Shock
30 April 1998
Pfizer's Impotence Pill Wins FDA Clearance
31 March 1998
MCA Rejects Scotia's Tarabetic
12 January 1998
NO Donor In Angina
25 November 1997
Gene Therapy Nears Reality For Cardiovascular Disease
20 November 1997
New Advances In The Treatment Of Sepsis?
9 October 1997
Zeneca Sees Strong Growth Against The Odds
8 August 1997
Ohmeda Files NO Therapy In USA
26 June 1997
Deja Vu As Yet Another Sepsis Drug Fails
26 May 1997
Investors Impressed With Glaxo Wellcome Pipeline
12 May 1997
NitroMed And Cordis In Restenosis Alliance
24 April 1997
NitroMed And J&J In NSAID Alliance
21 April 1997
Quinapril For Ischemic Heart Disease
19 August 1996
Ohmeda gets nitric oxide patent
29 January 1996
Glaxo Wellcome Unveils Revamped Pipeline
20 November 1995
Endothelin Receptor Antagonists; TAK-044
27 February 1995
Highlights Of SmithKline's R&D Portfolio
2 January 1995
British Heart Foundation Study
19 December 1994
FK506 TO PREVENT BRAIN CELL DEATH
3 October 1994
Hoechst's Propentofylline Set For Spring '95 Filing
3 October 1994
APEX SEPTIC SHOCK DRUG PATENTED
9 May 1994
WELLCOME LICENSES SEPSIS DRUG
4 April 1994
STROKE DISCOVERY TO BENEFIT GUILFORD?
14 February 1994
PRIMARY PREVENTION WITH B-MS' PRAVASTATIN
8 November 1993
HOECHST PHARMA "LEANER AND MORE FLEXIBLE"
1 November 1993
SCIOS NOVA FORMS CNS SUBSIDIARY
11 October 1993
NEUROSEARCH PRODUCT PIPELINE OVERVIEW
2 August 1993
WELLCOME R&D PIPELINE: PART 2
17 May 1993
BLOOD SUBSTITUTE FEARS UNFOUNDED?
19 April 1993
BLOOD SUBSTITUTE R&D: HOW IMPORTANT IS NO?
22 February 1993
Wellcome sepsis treatment
6 July 1992
NITRATES: OLD DRUGS, BUT ONES WITH A FUTURE
20 April 1992
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
